Pegloticase Plus Methotrexate Shows Hypertension Benefit in Gout Patients, with Richard Johnson, MD

An analysis of the pivotal MIRROR trial examining use of pegloticase plus methotrexate (Krystexxa) suggests use of the urate-lowering agent was associated with greater decreases in systolic blood pressure than pegloticase alone in patients with gout and uncontrolled hypertension.